Study Repo ts Immediate Pai F eedom i 14 of 15 Patie ts; all Patie ts Achieved Favo able Pai Outcomes at a Mea Six-Mo th Follow-Up
Multi-Co tact P obe Tech ology E abled Mappi g a d T eatme t of T igemi al Ne ve Dist ibutio s without Repeated P obe Repositio i g
EDEN PRAIRIE, Mi ., Oct. 29, 2026 (GLOBE NEWSWIRE) — Neu oO e Medical Tech ologies Co po atio (Nasdaq: NMTC) (“Neu oO e” o the “Compa y”), a medical tech ology compa y focused o the su gical diag osis a d t eatme t of eu ological diso de s, today a ou ced the publicatio of i itial cli ical esults evaluati g its O eRF® T igemi al Ne ve Ablatio System i the pee – eviewed jou al Pai Ma ageme t.
The a ticle,
T igemi al eu algia causes sudde , seve e, elect ic shock–like facial pai that ca i te fe e with eati g, speaki g, a d othe daily activities. Fo patie ts whose pai ca ot be adequately co t olled with medicatio , pe cuta eous adiof eque cy ablatio of the t igemi al e ve offe s a mi imally i vasive t eatme t optio .
Co ve tio al adiof eque cy systems typically use a si gle active tip that must be epositio ed to map a d t eat diffe e t t igemi al e ve dist ibutio s. O eRF’s thi -film, multi-co tact p obe allows physicia s to pe fo m multiple co tact-level mappi g a d lesio i g alo g a si gle fixed t ajecto y without epositio i g. The lack of eedi g to epositio the p obe may allow fo educed p ocedu e times, lowe umbe of a esthesia cycles a d, most impo ta tly, less discomfo t fo the patie t du i g the p ocedu e.
Immediate pai f eedom i 93.3% of patie ts: Fou tee of fiftee patie ts we e pai -f ee immediately afte t eatme t. The emai i g patie t expe ie ced pa tial i itial elief a d became pai -f ee app oximately o e week late .Favo able outcomes at follow-up: All 15 patie ts achieved a good cli ical outcome, defi ed as a Ba ow Neu ological I stitute pai sco e of I–IIIB, at a mea follow-up of six mo ths.Pai f eedom without medicatio : Eight patie ts, o 53.3%, we e pai -f ee a d taki g o pai medicatio at thei last follow-up. Six additio al patie ts we e pai -f ee while co ti ui g medicatio ; o e had esidual pai co t olled with medicatio .Mappi g a d t eatme t alo g a fixed t ajecto y: Co tact-level mappi g was achieved i eve y case, a d o patie t equi ed p obe epositio i g to map a d t eat multiple t igemi al dist ibutio s.No obse ved off-ta get lesio i g: The autho s epo ted o off-ta get lesio i g, ophthalmic complicatio s, o a esthesia dolo osa.Complicatio s: O e patie t developed a cheek hematoma du i g eedle i se tio a d epositio i g, which was t eated with ice a d esolved afte 1 week; this same patie t also developed t a sie t massete weak ess.
“T eati g t igemi al eu algia equi es ca eful localizatio of the e ve dist ibutio s espo sible fo each patie t’s pai ,” said Michael D. Staudt, MD, lead autho of the publicatio . “I this i itial se ies, the multi-co tact p obe allowed us to map a d t eat those dist ibutio s alo g a si gle fixed t ajecto y. The ea ly pai outcomes a e e cou agi g, a d lo ge follow-up will help us u de sta d the du ability of elief.”
Dave Rosa, P eside t a d Chief Executive Office of Neu oO e, added, “This publicatio adds pee – eviewed cli ical evide ce to ou expe ie ce with O eRF fo t igemi al eu algia. We a e e cou aged by the pai elief epo ted i this i itial coho t a d by the ability to map a d t eat multiple e ve dist ibutio s without epeated p obe epositio i g. These fi di gs suppo t co ti ued adoptio of the platfo m a d its pote tial to simplify the t eatme t wo kflow.”
The autho s emphasized that this was a small, et ospective se ies without a di ect compa iso g oup. La ge studies a d lo ge follow-up a e eeded to establish lo g-te m du ability, compa ative effective ess, a d the co t ibutio of co tact-specific mappi g to patie t outcomes.
The publicatio is available at: https://doi.o g/10.1080/17581869.2026.2748288.
The O eRF® T igemi al Ne ve Ablatio System leve ages Neu oO e’s p op ieta y adiof eque cy ablatio tech ology a d featu es a multi-co tact p obe desig ed to e able stimulatio , mappi g a d ablatio du i g t igemi al eu algia p ocedu es. The system is desig ed to st eamli e p ocedu al wo kflow by pote tially educi g the umbe of p obe epositio i g a d a esthesia cycles while p ovidi g physicia s with tempe atu e-mo ito ed adiof eque cy ablatio .
The Neu oO e O eRF® T igemi al Ne ve Ablatio System is i dicated fo use i p ocedu es to c eate adiof eque cy lesio s fo the t eatme t of pai , o fo lesio i g e ve tissue fo fu ctio al eu osu gical p ocedu es.
Neu oO e Medical Tech ologies Co po atio is a medical tech ology compa y focused o imp ovi g su gical ca e optio s a d outcomes fo patie ts suffe i g f om eu ological diso de s. Neu oO e ma kets a mi imally i vasive a d high-defi itio /high-p ecisio elect ode tech ology platfo m with fou FDA-clea ed p oduct families: Evo® Co tical Elect odes, Evo® sEEG Elect odes, O eRF® Ablatio System (fo b ai ), a d O eRF® T igemi al Ne ve Ablatio System.
Neu oO e has also developed the Ste eoCED™ platfo m fo ta geted i t ac a ial d ug delive y, which is cu e tly available fo a imal esea ch a d app oved i vestigatio al cli ical studies. Ste eoCED™ has ot bee clea ed o app oved by the FDA o a y othe egulato y age cy. These solutio s offe the pote tial to educe the umbe of hospitalizatio s a d su gical p ocedu es, lowe costs, a d imp ove patie t outcomes by offe i g diag ostic a d the apeutic fu ctio s. The Compa y is e gaged i esea ch a d developme t fo basive teb al e ve ablatio a d spi al co d stimulatio p og ams. Fo mo e i fo matio , visit mtc1.com.
This p ess elease may i clude fo wa d-looki g stateme ts withi the mea i g of Sectio 27A of the Secu ities Act of 1933, as ame ded, a d Sectio 21E of the Secu ities Excha ge Act of 1934, as ame ded. Except fo stateme ts of histo ical fact, a y i fo matio co tai ed i this p ess elease may be a fo wa d–looki g stateme t that eflects Neu oO e’s cu e t views about futu e eve ts a d a e subject to k ow a d u k ow isks, u ce tai ties a d othe facto s that may cause ou actual esults, levels of activity, pe fo ma ce o achieveme ts to be mate ially diffe e t f om the i fo matio exp essed o implied by these fo wa d-looki g stateme ts. I some cases, you ca ide tify fo wa d–looki g stateme ts by the wo ds o ph ases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “i te d,” “pla ,” “objective,” “a ticipate,” “believe,” “estimate,” “p edict,” “p oject,” “pote tial,” “ta get,” “seek,” “co template,” “co ti ue, “focused o ,” “committed to” a d “o goi g,” o the egative of these te ms, o othe compa able te mi ology i te ded to ide tify stateme ts about the futu e. Fo wa d–looki g stateme ts may i clude stateme ts ega di g patie t outcomes a d the pote tial fo lowe p ocedu e times, lowe umbe of a esthesia cycles a d less discomfo t fo the patie t du i g the p ocedu e. The dist ibutio ag eeme t does ot p ovide fo a y gua a teed pu chase o de s, mi imum pu chase commitme ts o gua a teed sales, a d the e ca be o assu a ce as to the level of sales, if a y, that will be ge e ated u de the a a geme t. Although Neu oO e believes that we have a easo able basis fo each fo wa d-looki g stateme t, we cautio you that these stateme ts a e based o a combi atio of facts a d facto s cu e tly k ow by us a d ou expectatio s of the futu e, about which we ca ot be ce tai . Ou actual futu e esults may be mate ially diffe e t f om what we expect due to facto s la gely outside ou co t ol, i cludi g isks that ou pa t e ships may ot facilitate the comme cializatio o ma ket accepta ce of ou tech ology; isks that ou tech ology will ot pe fo m as expected based o esults of ou p e-cli ical a d cli ical t ials; isks elated to u ce tai ties associated with the Compa y’s capital equi eme ts to achieve its busi ess objectives a d ability to aise additio al fu ds; the isk that we may ot be able to secu e o etai cove age o adequate eimbu seme t fo ou tech ology; u ce tai ties i he e t i the developme t p ocess of ou tech ology; isks elated to cha ges i egulato y equi eme ts o decisio s of egulato y autho ities; that we may ot have accu ately estimated the size a d g owth pote tial of the ma kets fo ou tech ology; isks elated to ou ability to p otect ou i tellectual p ope ty ights; a d othe isks, u ce tai ties a d assumptio s, i cludi g those desc ibed u de the headi g “Risk Facto s” i ou fili gs with the Secu ities a d Excha ge Commissio . These fo wa d–looki g stateme ts speak o ly as of the date of this p ess elease a d Neu oO e u de takes o obligatio to evise o update a y fo wa d–looki g stateme ts fo a y easo , eve if ew i fo matio becomes available i the futu e.
